1. ACKNOWLEDGEMENT TO REFEREES

   Acknowledgement to Referees 02 November 2017 Pages: 469 - 471

2. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf

   • Marco Ruella
   • Saad S. Kenderian

   Current Opinion 16 November 2017 Pages: 473 - 481

   

3. The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities

   • Paolo Martelletti

   Commentary 09 November 2017 Pages: 483 - 485

   

4. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress

   • Hsiangkuo Yuan
   • Clinton G. Lauritsen
   • Stephen D. Silberstein

   Review Article 07 November 2017 Pages: 487 - 501

5. Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

   • William M. Pardridge

   Review Article 24 October 2017 Pages: 503 - 519

   

6. Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

   • Penelope M. Drake
   • David Rabuka

   Review Article Open access 08 November 2017 Pages: 521 - 531

7. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK

   • Mohammed I. Aladul
   • Raymond W. Fitzpatrick
   • Stephen R. Chapman

   Original Research Article 10 November 2017 Pages: 533 - 544

   

8. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

   • Elisa V. Gomez
   • Jessie L. Bishop
   • Diane Phillips

   Original Research Article Open access 07 November 2017 Pages: 545 - 554

   

9. GP2015: An Etanercept Biosimilar

   • Emma D. Deeks

   Adis Biosimilar Brief Open access 23 September 2017 Pages: 555 - 558